Laparoscopic Cryoablation of Uterine Fibroids (UFREEZE-01)
This study is not yet open for participant recruitment.
Verified November 2012 by IceCure Medical Ltd.
Sponsor:
IceCure Medical Ltd.
Information provided by (Responsible Party):
IceCure Medical Ltd.
ClinicalTrials.gov Identifier:
NCT01735812
First received: November 26, 2012
Last updated: November 27, 2012
Last verified: November 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The goal of this study is to evaluate the safety & efficacy of cryoablation using IceCure medical's IceSense3™ device for the treatment of symptomatic uterine fibroids in a percutaneous lap-assisted approach.
| Condition | Intervention |
|---|---|
|
Symptomatic Uterine Fibroids |
Device: IceSense3 system |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Cryoablation of Symptomatic Uterine Fibroids Using the IceSense3™ System in a Percutaneous Laparoscopic-assisted Approach |
Further study details as provided by IceCure Medical Ltd.:
Primary Outcome Measures:
- Improvement in patient's fibroid-related quality of life [ Time Frame: 12 months ] [ Designated as safety issue: No ]To evaluate procedural efficacy by the improvement in patient's fibroid-related quality of life as assessed in scores of symptom severity subscale questionnaire (SSS-UFS-QOL) at 12 months post-treatment comparing to baseline score.
- Incidence, subsequent interventions and procedure-related adverse events [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]To evaluate procedural safety by monitoring incidence, subsequent interventions and procedure-related adverse events within 12 months of treatment
Secondary Outcome Measures:
- Reduction in fibroid volume [ Time Frame: 12 months ] [ Designated as safety issue: No ]Reduction in fibroid volume as measured by US/MRI imaging at 6 and 12 months follow-up post treatment comparing to baseline.
- Improvement in menstrual bleeding [ Time Frame: 12 months ] [ Designated as safety issue: No ]Improvement in menstrual bleeding compared to baseline as measured in chemical analysis (Alkaline haematin technique) at 6 and 12 months post treatment.
- Improvement in patient's fibroid-related quality of life [ Time Frame: 6 months ] [ Designated as safety issue: No ]Improvement in patient's fibroid-related quality of life as assessed in scores of symptom severity subscale questionnaire (SSS-UFS-QOL) at 6 months post-treatment comparing to baseline score.
Other Outcome Measures:
- Patient's and physician's overall treatment evaluation [ Time Frame: 12 months ] [ Designated as safety issue: No ]Patient's and physician's overall treatment evaluation and satisfaction will be assessed using a self-report questionnaire at 6 and 12 months post treatment.
- Patient blood loss [ Time Frame: 12 months ] [ Designated as safety issue: No ]Patient blood loss will be also evaluated by Hemoglobin (Hb) level measurements at 6 and 12 months post treatment and will be compared to baseline.
| Estimated Enrollment: | 30 |
| Study Start Date: | December 2012 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: symptomatic UF |
Device: IceSense3 system
The IceSense3™ is a modern cryosurgical device that was designed by IceCure Medical for a variety of applications.
|
Eligibility| Ages Eligible for Study: | 30 Years to 50 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Pre-menopausal woman between the ages of 30 and 50 (inclusive)
- Patient had completed her family planning and does not desire future childbearing.
- Patient is suffering from menorrhagia as a result of symptomatic uterine fibroids.
- Patient's uterus size is smaller than 18 gestational weeks.
- Patient wishes to preserve her uterus and avoid hysterectomy.
- Patient has 1-3 treatable uterine fibroids in size of up to 10cm measured by US/MRI.
- Overall treated fibroid volume is ≤ 3,138cm3 (width x length x height x 0.523)
- Patient has clinical menorrhagia as indicated by menstrual blood loss of ≥160 ml during one baseline cycle prior to treatment.
- Patient is able to visit the clinic as needed during the 1 year follow-up period following the treatment.
- The patient has been informed of the study and agrees to its provisions, and has signed an IRB approved written informed consent, including data privacy authorization.
Exclusion Criteria:
- Patient had not finished her family planning
- Patient was already treated for uterine fibroids in the past (UAE, myomectomy, HIFU,…) or undergone endometrial ablation.
- Patient had been treated with GnRH over the last 3 months.
- Patient has known symptomatic endometriosis that cannot be completely removed during laparoscopic procedure.
- Patient has known or suspected adenomyosis
- Patient had any active abdominal/pelvic inflammatory disease.
- Patient has known or suspected gynecologic malignancy.
- Patient with submucosal fibroids type "zero"
- Patient with undiagnosed vaginal bleeding
- Patient with blood clotting disorders
- Patients carrying contagious diseases such as Tuberculosis Hepatitis or AIDS.
- Patient participating in other trials using drugs or devices.
- Patient is unable to commit all study requirements including follow-up visits and questionnaires.
- Patient has any contraindication for laparoscopic surgery
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01735812
Contacts
| Contact: Elisabeth Sadka, Mrs | 972 4 623 0333 ext 223 | Elisabeth@Icecure-medical.com |
| Contact: Tal Avziz, Mr. | 972 4 623 0333 ext 127 | tal@icecure-medical.com |
Locations
| Israel | |
| Assaf Harofe | Not yet recruiting |
| Zrifin, Israel, 70300 | |
| Contact: Moty Pansky, Prof. | |
| Principal Investigator: Moty Pansky, Prof | |
Sponsors and Collaborators
IceCure Medical Ltd.
Investigators
| Principal Investigator: | Moty Pansky, Prof. | Assaf Harofe Hospital, Israel |
More Information
No publications provided
| Responsible Party: | IceCure Medical Ltd. |
| ClinicalTrials.gov Identifier: | NCT01735812 History of Changes |
| Other Study ID Numbers: | ICUFL-01 |
| Study First Received: | November 26, 2012 |
| Last Updated: | November 27, 2012 |
| Health Authority: | Israel: Ethics Commission |
Keywords provided by IceCure Medical Ltd.:
|
cryoablation uterine fibroid uterine myoma who completed her family planning but wishes to preserve her uterus |
Additional relevant MeSH terms:
|
Leiomyoma Myofibroma Neoplasms, Muscle Tissue Neoplasms, Connective and Soft Tissue |
Neoplasms by Histologic Type Neoplasms Neoplasms, Connective Tissue Connective Tissue Diseases |
ClinicalTrials.gov processed this record on June 17, 2013